Ascletis Pharma (HKSE:01672) Total Tax Payable : HK$4.35 Mil (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Ascletis Pharma Total Tax Payable?

Ascletis Pharma's Total Tax Payable for the quarter that ended in Dec. 2024 was HK$4.35 Mil.

Ascletis Pharma's quarterly Total Tax Payable declined from Dec. 2023 (HK$1.88 Mil) to Jun. 2024 (HK$0.43 Mil) but then increased from Jun. 2024 (HK$0.43 Mil) to Dec. 2024 (HK$4.35 Mil).

Ascletis Pharma's annual Total Tax Payable increased from Dec. 2022 (HK$1.73 Mil) to Dec. 2023 (HK$1.88 Mil) and increased from Dec. 2023 (HK$1.88 Mil) to Dec. 2024 (HK$4.35 Mil).

Ascletis Pharma Total Tax Payable Historical Data

The historical data trend for Ascletis Pharma's Total Tax Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascletis Pharma Total Tax Payable Chart

Ascletis Pharma Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Tax Payable

Get a 7-Day Free Trial

0.78

4.85

1.73

1.88

4.35

Ascletis Pharma Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Total Tax Payable	Get a 7-Day Free Trial												1.73	-	1.88	0.43	4.35

Ascletis Pharma Total Tax Payable Calculation

Total Tax Payable is the taxes liability owed to federal, state, and local tax authorities. It is the carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.

Ascletis Pharma Total Tax Payable Related Terms

Thank you for viewing the detailed overview of Ascletis Pharma's Total Tax Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Ascletis Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascletis Pharma Inc (HKSE:01672) » Definitions » Total Tax Payable

Comparable Companies

Traded in Other Exchanges

ASCLF:USA 2VJ:Germany

Address

198 Qidi Road, 12th Floor, Building D, HIPARK, Xiaoshan District, Zhejiang Province, Hangzhou, CHN, 311200

Website

https://www.ascletis.com

Ascletis Pharma Inc is an investment holding company. Along with its subsidiaries, it is engaged in the research and development, production, marketing, and sale of pharmaceutical products. It has three marketed products, i.e. Ritonavir tablets, GANOVO, and ASCLEVIR. It also has other drug candidates in its pipeline in their different stages of development such as ASC22, ASC10, ASC11, and ASC40 among others. Geographically, it operates in Mainland China and other countries.

Executives

Wu Jinzi Jason	2101 Beneficial owner
Wu Judy Hejingdao	2101 Beneficial owner
Jjw12 Limited
Lakemont Holding Llc
Jjw11 Limited
C-bridge Capital Gp, Ltd.	2201 Interest of corporation controlled by you
Fu Wei	2201 Interest of corporation controlled by you
Tf Capital Ii Ltd.	2201 Interest of corporation controlled by you
Tf Capital, Ltd.	2201 Interest of corporation controlled by you
Kang Hua Investment Company Limited	2201 Interest of corporation controlled by you
Yang Dan	2201 Interest of corporation controlled by you

Ascletis Pharma Headlines

No Headlines